7 results about "Aspartic Acid Proteases" patented technology

The present invention provides highly effective and safe means capable of preventing or treating an egg allergy in infants. An oral immunotolerance agent or a food composition for preventing or treating an egg allergy according to the present invention contains a degraded product of heat-denatured egg white with an aspartic protease (e.g. pepsin) or a metal protease (e.g. thermolysin).

The application relates to the field of genetic engineering, and discloses an Aspergillus niger, a construction method and application of the Aspergillus niger, and a method for producing citric acid and / or succinic acid. Aspergillus niger The Aspergillus niger is obtained by simultaneously overexpressing alpha-amylase and aspartic protease in a starting strain. The Aspergillus niger provided by the application can realize efficient degradation and conversion of starch by synergistically overexpressing amyA genes and pepA genes, solve the technical bottleneck that the original strain is limited in growth in a starch-based fermentation system and has insufficient acid production capacity, can efficiently produce succinic acid and citric acid by taking low-cost starch as the only carbon source, significantly reduce the industrial production cost of organic acid, and promote the green and sustainable upgrading of the fermentation industry.

An aspartic protease and the use of the aspartic protease in the hydrolysis of gluten. This protease can hydrolyze gluten and the gluten-derived immunogenic peptides at pH 2.0˜4.0. Also provided are methods for the production of the aspartic protease, including recombinant plasmids, transformants, and a purification method thereof; methods of using the aspartic protease to prepare drugs and oral enzyme supplements for treatment of diseases or discomforts related to gluten ingestion, such as celiac disease; and a method of using the asparic protease in food-processing process to remove or reduce gluten in foods or beverages.

The invention provides a sugarcane ScGIP1 gene, an encoded protein and application, and belongs to the technical field of genetic engineering. The nucleotide sequence of the ScGIP1 gene is as shown in SEQ ID NO. 1. The invention preliminarily reveals that the sugarcane aspartic protease ScGIP1 as a novel plant disease-resistant factor has potential application value in improvement of plant disease resistance, enriches functional cognition of aspartic protease in plant immune response, provides potential gene resources for disease prevention and control of sugarcane and other crops, and has broad application prospects. Good application prospects and popularization values are realized.

The present invention generally relates to aspartic proteases (EC 3.4.23) for producing cheese.

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising said modified proteins, their preparation and the use of such compositions in medicine. More specifically, the present invention relates to a modified Sap2 (Secretory Aspartic Protease 2 of Candida albicans) protein. The modified Sap2 protein can be used as other antigens, in particular as a carrier protein for carbohydrate antigens or other antigens lacking T cell epitopes.

To provide a drug delivery system to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction.SOLUTION: A drug delivery system comprises a first active pharmaceutical ingredient (API) and a sustained delivery component, wherein the first API is a peptide derivative of ciliary neurotrophic factor (CNTF) comprising the peptide sequence DGGL, and the first API is a peptide represented by SEQ ID NO: 2 (peptide 21: Ac-DGGLAG-NH2). The drug delivery system is used for injection into mammal eyes.SELECTED DRAWING: None